REGLAGENE
Reglagene leverages Quadruplex Master Switch Technology (QMST) to create new medicines that help cancer patients. Reglagene aspires to be the world’s leader in the creation of therapies that work through quadruplexes, DNA structures that selectively control the behavior of individual genes. Pharmaceutical companies now in-license most of their product portfolios from innovator companies like Reglagene, especially in the oncology sector. We will earn revenue by licensing the intellectual property (patents) around the new medicines we create to pharmaceutical partners, a $30B market. We are the ONLY company that harnesses Quadruplex Master Switch Technology to discover new medicines.
REGLAGENE
Industry:
Biotechnology Life Science
Founded:
2018-01-01
Address:
Arizona, Sonora, Mexico
Country:
Mexico
Website Url:
http://www.reglagene.com
Total Employee:
1+
Status:
Active
Contact:
(520) 235-0365
Email Addresses:
[email protected]
Total Funding:
546.41 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS GStatic Google Static Content
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Current Employees Featured
Founder
Official Site Inspections
http://www.reglagene.com Semrush global rank: 5.9 M Semrush visits lastest month: 1.4 K
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Reglagene"
Reglagene
Nov 13, 2024 · Reglagene is a therapeutics company that leverages its expertise in the design and development of brain penetrant medicines to create breakthrough therapies for the safe …See details»
Transforming Tubulin Therapy for Brain Diseases
The Reglagene team is dedicated to propelling the boundaries of medical science, improving the lives of patients, and making profound contributions to the field of brain cancer and brain inflammation. Of utmost importance, Reglagene …See details»
Transforming Tubulin Therapy for Brain Diseases - Reglagene
Reglagene’s first product is a novel, orally administered, well-tolerated, blood-brain barrier penetrant therapy for the treatment of brain cancers. Reglagene's medicines work through …See details»
Reglagene Company Profile 2024: Valuation, Funding & Investors
Operator of a therapeutics company intended to transform tubulin targeting therapy for central nervous system diseases.See details»
Reglagene - Crunchbase Company Profile & Funding
Reglagene mainly engages in transforming tubulin therapy for brain diseases. It leverages its expertise in the design and development of brain-penetrant medicines to create breakthrough …See details»
Reglagene Receives FDA Orphan Drug Designation for Innovative …
Jan 4, 2024 · Named as a recipient of a 2023 AZBio Fast Lane Award, Reglagene, Inc. is a ground-breaking therapeutics company designing small-molecule treatments to pass through …See details»
Reglagene - BIO International Convention | BIO
Jun 7, 2023 · Reglagene is a therapeutics company transforming tubulin targeting therapy for brain diseases. Reglagene’s lead program is a novel, orally administered, well tolerated, blood …See details»
Reglagene - LinkedIn
Reglagene is a therapeutics company that leverages its expertise in the design and development of brain penetrant medicines to create breakthrough therapies for the safe and effective treatment...See details»
Reglagene - Org Chart, Teams, Culture & Jobs | The Org
View Reglagene's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Richard Austin - CEO at Reglagene - The Org
Dr. Richard Austin is a Pharmaceutical R&D veteran with 25 years of experience ranging from the laboratory bench to management. His professional career began as a medicinal chemist with …See details»
Reglagene receives FDA Orphan Drug Designation for innovative …
Jan 12, 2024 · Reglagene's lead product, RGN6024, has received an exclusive orphan drug designation from the FDA. Find the full announcement below or on the EIN Presswire.See details»
Reglagene gets crucial TCA Orange County funding for FDA brain …
TUCSON, Ariz., Aug. 1, 2023 /PRNewswire/ -- Reglagene, Inc., researching breakthrough treatments for brain diseases, received a key investment from nationally known Tech Coast …See details»
Tucson startup Reglagene wins funding for drug development
Sep 30, 2024 · Tucson-based startup Reglagene Inc. has won a major investment from a California angel investor group to advance toward clinical studies of new treatments for brain …See details»
Reglagene, LLC - VentureRadar
Website: https://www.reglagene.com/ Pioneers transformative brain cancer treatment with an innovative tubulin-targeting, orally administered therapy that effectively penetrates and …See details»
Reglagene - CEO and Investor Conference 2025 - bcic.bio.org
Feb 27, 2024 · Reglagene is revolutionizing brain disease therapy by targeting tubulin with a groundbreaking class of selective inhibitors. Our novel compounds, led by RGN6024, offer a …See details»
Transforming Tubulin Therapy For Glioblastoma Executive Summary
Reglagene is actively raising a $5M equity investment to support this development phase. Reglagene will dose cancer patients who are candidates for tubulin-targeting therapy in Q4 …See details»
Tucson Tech: UA drug spinoff Reglagene aims to 'turn off' cancer
University of Arizona technology spinoff company Reglagene aims to combat cancer’s resistance to drugs with an approach that targets specific DNA structures in cancer genes known as …See details»
Transforming Tubulin Therapy for Brain Diseases - Reglagene
Reglagene has multiple orally administered, blood-brain barrier penetrant microtubule targeting agents that have the unique ability of reducing neuro-inflammation and are being developed …See details»
Preclinical development at 10% of the cost: How Did Reglagene …
Oct 31, 2023 · Richard Austin is the CEO of Reglagene, a therapeutics company developing brain-penetrating medicines to make breakthroughs in brain cancer treatments. In Today’s …See details»
Transforming Tubulin Therapy for Brain Diseases - Reglagene
Jun 5, 2024 · Reglagene's lead product, RGN6024, has received an exclusive orphan drug designation from the FDA. Read the full announcement here, or on the EIN Presswire. We’re …See details»